Archive: Company News
Eisbach Bio and MD Anderson Announce Strategic Collaboration to Develop Medicines Targeting Epigenetic Machinery in Oncology
Eisbach Bio GmbH and The University of Texas MD Anderson Cancer Center today announced a strategic research collaboration to jointly discover and develop precision oncology drugs that target synthetic lethal engines key to tumor genome evolution.
The agreement aligns the drug discovery and development expertise of MD Anderson’s Therapeutics Discovery division with the innovative discovery platform and allosteric assay technology of Eisbach to generate medicines that selectively disrupt genome replication and DNA repair in cancers harboring defined genetic alterations.
T-knife Therapeutics Appoints Ronald Krasnow, J.D., as General Counsel
T-knife Therapeutics, Inc., a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, today announced the appointment of Ronald Krasnow, J.D., who brings over thirty years of legal counsel and executive management experience to T-knife.
“I am pleased to welcome Ron to the senior leadership team at T-knife,” stated Thomas M. Soloway, Chief Executive Officer of T-knife. “Ron is a seasoned executive who has led the legal, compliance and business operations functions at several innovative biotech companies, and additionally has specialized expertise in patent law. As a rapidly growing organization with multiple pipeline programs, his contributions will be instrumental as we pursue our mission of developing best-in-class T-cell receptor (TCR) therapies to transform patient outcomes.”
BellaSeno Announces Publication of First-in-Human Data of its Lead Program Senella
— Successful initial treatment of pectus excavatum patient in Australia
— Data published in the European Journal of Plastic Surgery confirms Bellaseno’s novel approach in soft tissue engineering
BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced the publication of first-in-human data of its lead program Senella® in the European Journal of Plastic Surgery. In the trial, a 22-year old patient with severe pectus excavatum received a custom-made, 3D-printed, biodegradable and highly porous Senella® scaffold filled with autologous fat graft to correct her chest deformation.